Epilepsy is the most common chronic neurological condition in dogs, affecting an estimated 0.5–0.75% of the canine population. Management is pharmacological — anti-seizure medications (ASMs) are the foundation of epilepsy care and cannot be replaced by supplements. However, several supplements have genuine mechanistic rationale and, in the case of MCT oil, controlled clinical trial evidence in dogs specifically. Understanding what the evidence actually supports — and what risks to avoid — is essential for owners who want to contribute meaningfully to their epileptic dog's management.

Idiopathic epilepsy: the most common form

Idiopathic epilepsy (IE) — seizures without identifiable structural brain lesion or metabolic cause — is the predominant form in dogs. It is presumed genetic in origin, with clear breed predispositions: Labrador Retrievers, Golden Retrievers, German Shepherd Dogs, Border Collies, Australian Shepherds, Belgian Tervurens, Beagles, and Irish Setters all have documented elevated IE prevalence. Onset is characteristically between 1 and 5 years of age. Structural epilepsy (secondary to brain tumor, encephalitis, prior trauma) and reactive seizures (secondary to metabolic disease — hypoglycemia, hepatic encephalopathy) must be ruled out before IE is diagnosed — typically by MRI and CSF analysis.

Anti-seizure medication (phenobarbital as first-line, potassium bromide as second-line, levetiracetam, zonisamide as adjuncts) is indicated when seizures are frequent (more than one per month), severe (status epilepticus or cluster seizures), or progressive. Supplements are adjuncts added to — never substituted for — established ASM therapy.

MCT oil: the strongest supplement evidence in canine epilepsy

Medium-chain triglycerides (MCTs) — specifically caprylic acid (C8) and capric acid (C10) — are metabolized differently from long-chain fatty acids. They are transported directly to the liver via portal circulation (not via chylomicrons and lymphatics like long-chain fats), rapidly converted to ketone bodies (beta-hydroxybutyrate, acetoacetate), and exported to peripheral tissues including the brain as an alternative fuel source. Ketosis — whether from MCT supplementation or a ketogenic diet — is established as an anti-seizure strategy in human drug-resistant epilepsy, and the mechanism has been studied in dogs specifically.

A randomized, double-blind, placebo-controlled crossover trial in dogs with idiopathic epilepsy (Law et al., 2015, British Journal of Nutrition) demonstrated that MCT oil supplementation at 9% of daily caloric intake significantly reduced seizure frequency and seizure days compared to placebo. The reduction was meaningful: approximately 50% of MCT-supplemented dogs had a 50% or greater reduction in seizures. This is the highest-quality clinical evidence for any supplement in canine epilepsy.

The anti-seizure mechanism of ketones is multifactorial: ketone bodies reduce neuronal excitability by enhancing GABA-mediated inhibition, reducing glutamate-mediated excitation, and improving mitochondrial efficiency in neurons. MCTs also directly modulate AMPA-type glutamate receptors — a mechanism independent of ketone production.

MCT dose for dogs: Begin at 1–2% of daily caloric intake and increase over 2–4 weeks to a target of 9% of daily calories (the dose used in the clinical trial). Rapid introduction causes gastrointestinal upset — vomiting, diarrhea — in most dogs. Gradual titration is essential. Coconut oil is approximately 55–60% MCT (predominantly lauric acid, C12, which has a different metabolic fate than C8/C10 and does not produce significant ketosis) — it is not an equivalent MCT source. Use purified MCT oil (C8/C10 dominant) for anti-seizure purposes.

DHA: neuronal membrane maintenance

DHA (docosahexaenoic acid) constitutes approximately 15–20% of the fatty acid content of neuronal cell membranes — concentrated in synaptic vesicle membranes and myelin sheaths. Membrane DHA content influences neuronal excitability: DHA-enriched membranes modulate voltage-gated sodium and calcium channels, and adequate DHA availability supports inhibitory neurotransmission. Seizure propagation requires neuronal membranes to sustain rapid, repetitive depolarization — DHA's membrane-stabilizing properties theoretically reduce the propagation efficiency of seizure activity.

Direct clinical evidence for DHA as an anti-seizure supplement in dogs is limited. The mechanistic rationale is strong, and DHA supplementation is broadly recommended in veterinary neurology as a safe, beneficial adjunct with no interaction with ASMs. The neuroprotective effect — supporting neuronal membrane integrity against the oxidative damage caused by seizure activity itself — is a secondary rationale. Seizures generate significant neuronal oxidative stress; DHA, as a component of neuronal membrane phospholipids, is consumed and requires replenishment.

Dose: omega-3 supplementation at therapeutic range (40mg/lb EPA+DHA daily) is appropriate. Fish oil and algae oil are the effective sources — flaxseed oil provides ALA which dogs convert to DHA at less than 5% efficiency.

Taurine: neuronal stability

Taurine is the most abundant free amino acid in the brain, with high concentrations in areas of dense neuronal activity. It functions as an inhibitory neuromodulator — taurine activates glycine receptors and GABA-A receptors, contributing to inhibitory tone in the CNS. Taurine deficiency has been associated with seizure susceptibility in rodent models, and taurine is often mentioned as a supportive supplement for epileptic dogs. Clinical evidence in dogs is anecdotal rather than trial-derived, but the mechanism is sound and the safety profile is excellent.

Taurine is synthesized endogenously from methionine and cysteine, but synthesis may be insufficient in dogs on low-protein diets, grain-free diets (which have been associated with taurine-deficient cardiomyopathy), or dogs with GI malabsorption. Supplementation at 250–500mg twice daily for a medium-sized dog is a reasonable adjunct — low-risk and potentially supportive of inhibitory neuronal tone.

Phenobarbital and supplement interactions

Phenobarbital is a hepatic enzyme inducer (CYP enzyme induction) — it increases the metabolic rate of many compounds processed by the liver, including some B vitamins. Documented effects include:

• B vitamin depletion: Phenobarbital accelerates folate and B12 metabolism. Long-term phenobarbital therapy is associated with reduced folate status in human epileptic patients; the same mechanism applies in dogs. B vitamin supplementation (B complex at veterinary-appropriate doses) is relevant for dogs on long-term phenobarbital.
• CoQ10: Phenobarbital may reduce CoQ10 synthesis or availability through hepatic enzyme induction — documented in human epilepsy patients. CoQ10 (ubiquinol, 2–3mg/kg daily) is a rational adjunct for dogs on chronic phenobarbital, particularly older dogs whose CoQ10 synthesis is already declining.
• Vitamin D: Phenobarbital accelerates vitamin D metabolism to inactive forms — relevant for dogs in low-UV environments or with limited outdoor exposure.

None of these depletions are acutely dangerous, but they compound over years of therapy. Dogs on long-term phenobarbital (more than 6 months) benefit from supplementation that addresses these metabolic effects.

What to avoid: seizure threshold-lowering supplements

Several compounds are established proconvulsants — they lower the seizure threshold and should never be given to epileptic dogs:

• Rosemary (high-dose): Rosemary extract contains camphor and 1,8-cineole — compounds with known proconvulsant activity in rodent models. Low-level rosemary as a food flavoring is not equivalent to concentrated rosemary extract supplements. Avoid rosemary-containing supplements, rosemary-based flea products applied to epileptic dogs, and rosemary-heavy herbal preparations.
• Camphor: Present in some topical preparations and some herbal supplements — direct proconvulsant; avoid entirely in epileptic dogs.
• Pennyroyal oil: Neurotoxic; contraindicated in all dogs.
• High-dose essential oil supplements: Many essential oils contain terpenes with CNS-stimulating or proconvulsant properties; avoid oral essential oil supplements in epileptic dogs unless specifically reviewed by the managing veterinarian.

CBD: a note on scope

Cannabidiol (CBD) has been investigated as an anti-seizure adjunct in dogs — a 2019 Colorado State University clinical trial (McGrath et al.) showed a significant reduction in seizure frequency in CBD-treated dogs vs. placebo. The evidence is promising. However, CBD is not FDA-cleared for veterinary use, dosing and product quality standards are inconsistent across the commercial market, and CBD interacts with hepatic CYP450 enzymes relevant to phenobarbital metabolism. CBD in epileptic dogs requires veterinary supervision and is outside the scope of a general supplement guide — discuss specifically with your neurologist or managing veterinarian.

The epilepsy supplement protocol

• MCT oil — highest clinical evidence; titrate slowly to 9% of daily calories over 4 weeks; use C8/C10 MCT oil, not coconut oil
• Omega-3 (EPA+DHA) — DHA for neuronal membrane maintenance and anti-seizure propagation support; therapeutic dose
• Taurine — inhibitory neuromodulator support; 250–500mg twice daily for medium breed
• B complex + CoQ10 — for dogs on long-term phenobarbital to address documented depletion patterns

All supplement additions in epileptic dogs should be documented and reported to the managing veterinarian. Any change in seizure frequency after a supplement introduction — in either direction — is clinically relevant information for ASM dose management.

Related: omega-3 guide · CoQ10 guide · omega-3 complete guide · senior dog supplement guide · Belgian Malinois health guide.